BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading phage therapy pipeline Recent stockholder vote approves conversion of Series X Non-Voting Convertible Preferred Stock (issued upon merger with Adaptive Phage Therapeutics and concurrent financing) to BiomX's common stock Company will host a conference call and webcast today at 8:00 am ET GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a cl ...

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it intends to effect a one-for-ten reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol "PHGE" and will begin trading on a spli ...

GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received a notification (the "Acceptance Letter") from the NYSE American LLC (the "NYSE American"), dated July 23, 2024, stating that the NYSE American has accepted the Company's previously submitted plan to regain compliance with the NYSE American's l ...

"We are pleased the NYSE American has accepted our Plan to regain compliance," commented Jonathan Solomon, Chief Executive Officer of BiomX. "We intend to take all reasonable measures available to us and have already begun implementing our Plan, including by obtaining stockholders' approval for conversion of the Company's outstanding Series X Convertible Preferred Stock to Common Stock, as announced earlier this month." During the Plan Period, the Company will be subject to periodic review by the NYSE Ameri ...

BiomX's Series X Preferred Stock was issued upon BiomX's acquisition of Adaptive Phage Therapeutics, Inc. ("APT") and a concurrent $50 million financing (the "Financing"), which were consummated in March 2024. As a result of the stockholder vote approving the conversion of BiomX's Series X Preferred Stock, each share of Series X Preferred Stock issued in the APT acquisition and the private placement will be converted into 1,000 shares of BiomX common stock, subject to certain beneficial ownership limitation ...

Core Viewpoint - BiomX Inc. has received approval from its stockholders to convert its Series X Non-Voting Convertible Preferred Stock into common stock, which is expected to enhance its compliance with NYSE American listing requirements [1][2][5]. Group 1: Stockholder Vote and Conversion - The stockholder vote approved the conversion of BiomX's Series X Preferred Stock into common stock, allowing for the conversion of up to 256,887 shares into 256,887,000 shares of common stock [5]. - This conversion is a result of the financing associated with the acquisition of Adaptive Phage Therapeutics, Inc. and is expected to positively impact the company's balance sheet by classifying certain proceeds as stockholders' equity [2][5]. Group 2: Compliance with NYSE American - Following the stockholder vote, BiomX anticipates regaining compliance with NYSE American's requirement for listed companies to maintain stockholders' equity of at least $2 million [2]. - The company had previously been notified of non-compliance and submitted a plan to address this issue, awaiting acceptance from NYSE American [2]. Group 3: Company Overview and Future Prospects - BiomX is focused on developing novel phage therapies targeting pathogenic bacteria, with two advanced Phase 2 clinical candidates expected to have significant readouts in the coming year [6]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets, aiming to address chronic diseases with unmet medical needs [6].

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification ("the Notice") from the NYSE American LLC ("NYSE American"), dated May 23, 2024, stating that the Company is no longer in compliance with continued listing standards, as set forth in Sections 1003(a) ...

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present at two upcoming conferences data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in an oral pres ...

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business and program updates for the first quarter ended March 31, 2024. BiomX is announcing merged financial reporting for the first time following the closing of its merger with Adaptive Phage Therapeutics, ...

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a conference call and webcast today at 8:00 am ET Cystic Fibrosis (BX004) In January 2024, the Company announced that BX004 was granted Orphan Drug Designation by the United States Food and Drug Administration ("FDA"), for the treatment of chronic pulmonary infection caused by P. aeruginosa in patients with CF. In Apri ...